HBIO Announces $87M FY25 Revenue, $8M Adjusted EBITDA, 58% Gross Margin, 54% Adjusted EBITDA Margin, 10K+ Customers, $3M EBITDA Savings from Plant Closure, $7.5M Convertible Note Investment, New CEO John Duke, Expanded Board, Focus on Translational Science, Guides 58-60% FY26 Rev
Harvard Bioscience Inc · LABORATORY ANALYTICAL INSTRUMENTS · Now $6.40
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS